PNM 37.25    Updated: 04-28-2017 $PNM Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
18
PNM 37.25    Updated: 04-28-2017 $PNM
Last Trade: 4/28/2017
Last 37.25   
Open 37.40
Previous Close 37.25
Day High / Low 38.39 / 37.20
Year High / Low 38.39 / 30.89
Volume 612,136
Projected Volume 612136 (103%)
# of Trades / Projected 2,945 / 2,945
Dividend / Yield 0.96 / 2.59%
Abnormal Activity NONE
Abnormal Volume NO
Gap NONE
Candle BEARISH
Volatility Today LOW
Volatility Yesterday LOW
Price Relativity
From 40 Day High 98%
From 80 Day High 98%
From 150 Day High 98%
From 40 Day Low 104%
From 80 Day Low 111%
From 150 Day Low 120%
Pivot Analysis
Price Pivot $ 37.61
Day Resistance 1 $ 38.03
Day Support 1 $ 36.84
Day Resistance 2 $ 38.80
Day Support 2 $ 36.42
Consolidations
Short Term YES
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 595,636
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 586,317
Today / 150 Day Avg Vol ABOVE
Abnormal Volume NO
William Volume Accumulation bullish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bearish
40 Day Trend bullish
100 Day Trend bullish
Stochastics neutral
RSI bearish
MACD bullish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bullish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today LOW
Volatility Index Yesterday LOW
10 Day Volatility DECREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ImmVira's Bladder Cancer Trials: Promising Data Revealed

Updated Category News Views 3

Tackling Bladder Cancer with Innovation In a world where every budding biotech claims they're on the cusp of revolutionizing cancer treatment, ImmVira's recent data on their oncolytic immunotherapy, MVR-T3011, stands out like a bright flash in a murky market. Presented at the prestigious European Society for Medical Oncology (ESMO) Congress 2026 in Suzhou, these updates...

Continue Reading
Resilience: From Trauma to Shielding Powerhouses

Updated Category News Views 6

A Childhood Steeped in Shadows If you think it's all Wall Street pulse for me, think again. Sometimes you stumble upon stories that hit the gut with more force than any market crash. Enter David Seymour's tale, wrapped up in his newly released autobiography from Palmetto Publishing, bearing the intriguingly gritty title: From paperboy to Secret Service Special Agent. This...

Continue Reading
ThreatLocker Launches Global AI Awareness Campaign

Updated Category News Views 4

Kicking Off with Pop Culture Pizzazz Ah, the sweet sound of a campaign that knows how to tug at the heartstrings of nostalgia. ThreatLocker has gotten creative with its latest strategy to get people buzzing about AI safety. They're unleashing a worldwide campaign themed around 'Terminator 2.' Now that's a throwback! If you've ever caught yourself wide-eyed at the edge of...

Continue Reading
Camel Group Expands Battery Portfolio at Canton Fair

Updated Category News Views 3

A Grand Display at the Canton Fair Well, here's one you don't see every day: Camel Group putting on quite the show at the 140th China Import and Export Fair, better known to us as the Canton Fair. Kicked off on October 15, 2026, in Guangzhou, this grand event paraded 'Advanced Manufacturing' as its theme, and Camel's booth was packed to the brim with what might just be...

Continue Reading
ZPMC's Wind Power and Port Projects Earn Top Honors

Updated Category News Views 1

Wind Farms and Ports: A Winning Formula National applause rings out for Shanghai Zhenhua Heavy Industries Co., Ltd. (ZPMC) as they snagged top honors in the recent National Quality Engineering Awards. It's about time folks recognized the heavy lifting these projects do in reshaping our energy and port infrastructure. Two of their standout projects walked away with...

Continue Reading
Encompass Health Expands With Texas Rehab Hospital

Updated Category News Views 6

A New Chapter in San Antonio's Healthcare Landscape Breaking ground in Texas, Encompass Health has unveiled its latest addition: a 50-bed hospital in San Antonio's Westover Hills. With sheer determination, the largest owner of inpatient rehabilitation hospitals in the U.S. has made its mark, and this isn't just any facility—at over 54,000 square feet, it's a hub for...

Continue Reading
Union Alarmtronic Joins Forces with Pye-Barker in Key Sale

Updated Category News Views 3

A Key Merger in Security Sector Here's a deal that's got the market talking: Union Alarmtronic, a stalwart in the security systems arena, has tied the knot with Pye-Barker Fire & Safety, one of the biggest names in fire protection and life safety. This move isn't just another line in the 'mergers & acquisitions' logbook; it's a strategic shift that underscores the growing...

Continue Reading
Duni Group Faces Ups and Downs in Q3 2026

Updated Category News Views 1

Navigating Choppy Waters: Duni's Third Quarter 2026 Alright, folks, let's dive into the latest from Duni Group—a company feeling the pinch but pushing through with some resilience. The third quarter 2026 report has just landed, and while some numbers are headed up, plenty are a bit of a gut punch. This isn't a crisis, but it's no smooth sailing either. Let's cut through...

Continue Reading
Groundbreaking Sale: Lani Automotive Acquires Iowa Dealership

Updated Category News Views 6

A shift in the automotive retail world takes place with Lani Automotive Group's latest move. They've just picked up their first franchised dealership, Mount Pleasant Chevrolet GMC Chrysler Dodge Jeep Ram in Iowa. It's a mouthful, sure, but it packs a punch in terms of potential growth. Why This Sale Stands Out The deal was brokered by Performance Brokerage Services, which...

Continue Reading
Marengo: Bold Moves in TMB-H Tumor Treatment

Updated Category News Views 0

A New Hope for Tough Tumors? Marengo Therapeutics is stirring up the oncology world with some intriguing Phase 2 results from their STARt-001 clinical trial, revealing invikafusp alfa's potential as a single-agent therapy. This hasn’t been a walk in the park, mind you; we're talking about dealing with TMB-H solid tumors that typically thumb their noses at immune...

Continue Reading
iv>